Osteogenesis Imperfecta

This comprehensive genetic disorder topic provides Zambian tertiary nursing and medical students with detailed understanding of osteogenesis imperfecta (OI)—a heterogeneous group of inherited connective tissue disorders characterized by brittle bones and increased fracture susceptibility, resulting primarily from defects in type I collagen synthesis, structure, or processing. For Zambian healthcare students preparing for examinations in pediatrics, genetics, orthopaedics, and rehabilitation, mastery of OI is essential for accurate diagnosis, appropriate genetic counseling, multidisciplinary management, and recognition of the expanding phenotypic spectrum beyond the classic 'brittle bone' presentation. The fundamental pathophysiology involves quantitative or qualitative abnormalities of type I collagen—the predominant protein in bone matrix, skin, sclera, tendons, and ligaments. Type I collagen is a triple helix composed of two α1(I) chains and one α2(I) chain, encoded by COL1A1 (chromosome 17) and COL1A2 (chromosome 7), respectively. The classic forms of OI (80-90%) result from autosomal dominant mutations in these genes. Glycine substitutions within the Gly-X-Y repeating triple helix motif disrupt helix folding and secretion, producing structurally abnormal collagen that incorporates into matrix and exerts dominant-negative effects. Haploinsufficiency mutations produce reduced quantity of structurally normal collagen, typically causing milder phenotypes. Autosomal recessive forms involve mutations in genes essential for collagen processing (CRTAP, P3H1, PPIB—encoding proteins of the prolyl 3-hydroxylation complex), chaperone function (SERPINH1, FKBP10), or osteoblast differentiation (SP7, WNT1, BMP1). The clinical classification has evolved from the traditional Sillence types (I-IV) to encompass over 20 genetically-defined subtypes, though the Sillence system remains clinically useful. Type I (mild, non-deforming): normal height or mild short stature, blue sclerae, hearing loss in 50%, dentinogenesis imperfecta uncommon, fractures decrease post-puberty. Type II (perinatal lethal): extreme bone fragility with intrauterine fractures, beaded ribs, compressed femurs, pulmonary hypoplasia, universally fatal. Type III (progressively deforming): severe short stature, triangular facies, severe scoliosis, dentinogenesis imperfecta common, sclerae variable (blue at birth, normalizing with age), cumulative fracture burden causes progressive deformity and mobility impairment. Type IV (moderate): variable short stature, mild-moderate scoliosis, grey/white sclerae, dentinogenesis imperfecta common, fracture frequency variable. Type V: distinctive hypertrophic callus formation following fractures, interosseous membrane ossification, radio-opaque metaphyseal band, normal sclerae, no dentinogenesis, autosomal dominant with unique cause (IFITM5 mutation). Extraskeletal manifestations are diagnostically important: blue sclerae result from increased transparency of thinned connective tissue overlying underlying choroidal vessels; dentinogenesis imperfecta produces opalescent, discolored, fragile teeth from abnormal dentin; hearing loss (conductive, sensorineural, or mixed) typically presents in second-third decade; ligamentous laxity causes joint hypermobility and flat feet; skin thinning and easy bruising reflect dermal collagen deficiency; vascular fragility may cause easy bruising; cardiac valve abnormalities (aortic/mitral regurgitation) occur in some adults. Diagnosis is primarily clinical based on family history, fracture history, blue sclerae, and radiographic findings. Radiographic features include generalized osteopenia, multiple fractures at various healing stages, wormian bones (intrasutural skull bones), compression vertebrae, bowing long bones, and protrusio acetabuli. Dual-energy X-ray absorptiometry reveals low bone mineral density for age. Biochemical testing (collagen analysis from skin fibroblast culture) and molecular genetic testing confirm diagnosis and establish inheritance pattern for genetic counseling. Differential diagnosis includes child abuse (non-accidental injury)—a critical distinction with profound medical, legal, and social implications. Distinguishing features of OI include blue sclerae, dentinogenesis imperfecta, positive family history, wormian bones, and absence of characteristic abusive fracture patterns (posterior rib fractures, metaphyseal corner fractures, fractures in non-ambulatory infants). Management is multidisciplinary, requiring coordinated care from pediatrics, orthopaedics, physiatry, dentistry, audiology, and genetics. Bisphosphonates are the mainstay of pharmacological therapy, increasing cortical thickness and vertebral body height, reducing fracture incidence, and improving mobility and quality of life—though they do not correct the underlying collagen defect. Intravenous pamidronate or zoledronic acid cycles are standard; oral alendronate or risedronate are alternatives. Orthopaedic management emphasizes fracture care (often with telescoping intramedullary rods to maintain alignment despite bone growth), correction of deformities (osteotomies), and scoliosis surgery. Physical and occupational therapy maximize functional independence, strengthen muscles, and teach safe mobility strategies. Dental care addresses caries, malocclusion, and crowns for dentinogenesis imperfecta. Audiological monitoring and hearing aids address progressive hearing loss. Genetic counseling provides families with recurrence risk information and prenatal/preimplantation genetic diagnosis options. For Zambian nurses and clinicians, comprehensive OI knowledge enables early recognition of mild forms presenting with recurrent fractures in otherwise healthy children, appropriate diagnostic workup to distinguish OI from non-accidental injury, initiation of bisphosphonate therapy, coordination of multidisciplinary care, and provision of supportive, non-stigmatizing family education—improving outcomes and quality of life for affected individuals across the phenotypic spectrum.